Author:
Berta Judit,Török Szilvia,Tárnoki-Zách Júlia,Drozdovszky Orsolya,Tóvári József,Paku Sándor,Kovács Ildikó,Czirók András,Masri Bernard,Megyesfalvi Zsolt,Oskolás Henriett,Malm Johan,Ingvar Christian,Markó-Varga György,Döme Balázs,László Viktória
Abstract
AbstractApelin, a ligand of the APJ receptor, is overexpressed in several human cancers and plays an important role in tumor angiogenesis and growth in various experimental systems. We investigated the role of apelin signaling in the malignant behavior of cutaneous melanoma. Murine B16 and human A375 melanoma cell lines were stably transfected with apelin encoding or control vectors. Apelin overexpression significantly increased melanoma cell migration and invasion in vitro, but it had no impact on its proliferation. In our in vivo experiments, apelin significantly increased the number and size of lung metastases of murine melanoma cells. Melanoma cell proliferation rates and lymph and blood microvessel densities were significantly higher in the apelin-overexpressing pulmonary metastases. APJ inhibition by the competitive APJ antagonist MM54 significantly attenuated the in vivo pro-tumorigenic effects of apelin. Additionally, we detected significantly elevated circulating apelin and VEGF levels in patients with melanoma compared to healthy controls. Our results show that apelin promotes blood and lymphatic vascularization and the growth of pulmonary metastases of skin melanoma. Further studies are warranted to validate apelin signaling as a new potential therapeutic target in this malignancy.
Funder
Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
János Bolyai Research Scholarship of the Hungarian Academy of Sciences
The Mats Paulsson Trust
The Stefan Paulsson Trust
Fru Berta Kamprads Stiftelse
Austrian Science Fund
ÚNKP-19-4 New National Excellence Program of the Ministry for Innovation and Technology
Publisher
Springer Science and Business Media LLC
Reference71 articles.
1. Emmett, M. S., Dewing, D. & Pritchard-Jones, R. O. Angiogenesis and melanoma—from basic science to clinical trials. Am. J. Cancer Res. 1, 852–868 (2011).
2. Finn, L., Markovic, S. N. & Joseph, R. W. Therapy for metastatic melanoma: the past, present, and future. BMC Med. 10, 23. https://doi.org/10.1186/1741-7015-10-23 (2012).
3. Grossman, D. & Altieri, D. C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 20, 3–11 (2001).
4. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516. https://doi.org/10.1056/NEJMoa1103782 (2011).
5. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330. https://doi.org/10.1056/NEJMoa1412082 (2015).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献